Hemophilia A

Quality of Life Study of Helixate NexGen
NCT01053715 | PHASE 4 | OBSERVATIONAL

The aim of this study is to describe Health Related Quality of Life (HRQoL) in adolescents and adults with Hemophilia A treated prophylactically or on-demand with Helixate NexGen. The study will also assess the kinds of determinants, including key transitional life events, that might impact HRQoL in this patient population.

Trial Information
31 Sites
78 Participants
Recruiting
14 Years to 35 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

SUBMIT
CSLB Study Site
Graz,Austria
CSLB Study Site
Grieskirchen,Austria
CSLB Study Site
Innsbruck,Austria
CSLB Study Site
Klagenfurt,Austria
CSLB Study Site
Linz,Austria
CSLB Study Site
St. Pölten,Austria
CSLB Study Site
Vienna,Austria
CSLB Study Site
Vienna,Austria
CSLB Study Site
Vienna,Austria
CSLB Study Site
Edegem,Belgium
CSLB Study Site
Leuven,Belgium
CSLB Study Site
Amiens,France
CSLB Study Site
Poitiers Cedex,France
CSLB Study Site
Rouen,France
CSLB Study Site
Strasbourg,France
CSLB Study Site
Valence,France
CSLB Study Site
Berlin,Germany
CSLB Study Site
Bonn,Germany
CSLB Study Site
Bremen,Germany
CSLB Study Site
Delmenhorst,Germany
CSLB Study Site
Göttingen,Germany
CSLB Study Site
München,Germany
CSLB Study Site
Genova,Italy
CSLB Study Site
Milan,Italy
CSLB Study Site
Napoli,Italy
CSLB Study Site
Palermo,Italy
CSLB Study Site
Badajoz,Spain
CSLB Study Site
Jaen,Spain
CSLB Study Site
Valencia,Spain
CSLB Study Site
St. Gallen,Switzerland
CSLB Study Site
Zürich,Switzerland

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov